News - Johnson & Johnson


Current filters:

Johnson & Johnson

Popular Filters

280 to 301 of 301 results

Opportunity in hepatitis C market for recently-approved Victrelis and Incivek; report


Results from an on-line survey fielded just prior to the US Food and Drug Administration approval of…

Anti-viralsIncivekJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceuticalVertexVictrelis

Synthes and Eli Lilly to collaborate on osteoporosis treatments, including Forteo


Swiss medical device firm Synthes (SIX: SYST.VX) and US drug major Eli Lilly (NYSE: LLY) have signed…

Anti-Arthritics/RheumaticsEli LillyForsteoForteoJohnson & JohnsonMarkets & MarketingPharmaceuticalResearchSynthes

PATH MVI partners with GSK and Crucell to develop second-generation vaccine against malaria


The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with…

CrucellGlaxoSmithKlineJohnson & JohnsonPharmaceuticalResearchTropical diseasesVaccines

Pharma majors slash vaccine prices to poorest countries


Several pharmaceutical majors, including the UK’s GlaxoSmithKline (LSE: GSK), US giants Merck &…

GardasilGlaxoSmithKlineGlobalJohnson & JohnsonMerck & CoPharmaceuticalPricingRotarixSanofiSanofi PasteurVaccines

Johnson & Johnson faces $327 million penalty over Risperdal marketing


Civil penalties amounting to just over $327 million have been announced in the case of State of South…

Johnson & JohnsonLegalNeurologicalNorth AmericaOrtho-McNeil-JanssenPharmaceuticalRisperdal

AVEO Pharma licenses RON-targeted antibodies to Johnson & Johnson unit for up to $555 million


In a second significant deal this year, US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)…

AVEO PharmaceuticalsCentocor Ortho BiotechJohnson & JohnsonLicensingOncologyPharmaceutical

Johnson & Johnson highlights R&D pipeline with plans to file for 11 drug approvals by 2015; GAVI seat for Crucell


US health care major Johnson & Johnson (NYSE: JNJ) yesterday reviewed its growth strategies for its Pharmaceuticals…

Antibiotics and Infectious diseasesCardio-vascularImmunologicalsJohnson & JohnsonOncologyPharmaceuticalResearchVaccines

US Presidential visit to UK underlines cooperation in science, innovation and higher education


The joint statement agreed yesterday by UK Prime Minister David Cameron and US President Barack Obama,…

EuropeJohnson & JohnsonNorth AmericaPharmaceuticalResearch

J&J Cilag unit buys Russian OTC brands from J B Chemicals for $260 million


US health care giant Johnson & Johnson’ (NYSE: JNJ) Switzerland-based Cilag GmbH International has…

Cilag GmbHEuropeJ B Chemicals & PharmaceuticalsJohnson & JohnsonMergers & AcquisitionsPharmaceutical

US FDA approves Johnson & Johnson’s novel AIDS drug Edurant; expands use of Pfizer’s Sutent


The US Food and Drug Administration on Friday approved US health care giant Johnson & Johnson’s…

Anti-viralsEdurantJohnson & JohnsonNorth AmericaOncologyPfizerPharmaceuticalRegulationrilpivirineSutentTibotec

Bayer/Ortho-McNeil’s VTE drug Xarelto will earn peak-year sales of $500 million to $1 billion


Following its expected launch in the USA in 2012 for venous thromboembolism (VTE) prophylaxis in medically…

BayerCardio-vascularEliquisJohnson & JohnsonMarkets & MarketingOrtho-McNeilPharmaceuticalXarelto

Johnson & Johnson unit recalls batches of “smelly” AIDS drug Prezista


Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), which…

Anti-viralsJanssen-CilagJohnson & JohnsonPharmaceuticalPrezistaRegulation

Highlights from Digestive Disease Week


The 2011 Digestive Disease Week meeting in Chicago, USA, heard a number of interesting presentations…

Abbott LaboratoriesDificidGastro-intestinalsJohnson & JohnsonLubiprostoneOptimer PharmaceuticalsPharmaceuticalRemicadeResearchResolorShireStelara InjectionSucampo

Impax Labs sued again by J&J unit Alza over generic Concerta


USA-based Impax Laboratories (Nasdaq: IPXL) confirmed on Friday that Alza Corp, a division of health…

ALZA CorpConcertaGenericsImpax LaboratoriesJohnson & JohnsonLegalNeurologicalNorth AmericaPatentsPharmaceuticalTeva Pharmaceutical Industries

Johnson & Johnson unit voluntarily withdraws NDA for trabectedin


Centocor Ortho Biotech Products, a division of US health care giant Johnson & Johnson (NYSE: JNJ), says…

Centocor Ortho BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationtrabectedinYondelisZeltia

Johnson & Johnson to buy orthopedic device maker Synthes for $21.3 billion


Following earlier speculation, this morning, US diversified health care giant Johnson & Johnson (NYSE:…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

280 to 301 of 301 results

Company Spotlight



Back to top